NEW YORK, NY--(Marketwire - Nov 7, 2012) - Biotechnology companies are performing well as a whole at the moment but a variety of factors threaten to undo the industry's momentum. Technological turnover, competitive pressure and the need to get new products to market are all making it difficult to widen margins. Players in the Biotech space like Arena Pharmaceuticals Inc. and ARIAD Pharmaceuticals Inc. are contending admirably with these headwinds at the moment though. StBulls.com has initiated technical analysis on Arena Pharmaceuticals Inc. (NASDAQ: ARNA) and ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA) which serves the Biotechnology industry. These reports are free upon registration at
www.StBulls.com enthuses to bring the best from the internet under one roof, providing you with a one click opportunity to view what the market and financial researchers globally have to say about any particular bellwether stocks in any given financial environment. We work with a number of financial professionals and a dedicated team of researchers that use their acute knowledge to help you manage your understanding of the market. To be part of this community please sign up at
The trouble created by technological turnover is most evident in the diagnostic side of the industry. Not only are new products coming out at a faster rate but they are also able to complete tasks at a fraction of the cost of the previous generation.
Competitive threats and the need to get new drugs to market are more of a factor in the drug side of the industry. Acquisition activity remains strong as many companies look to quickly expand their portfolio of offerings and stave off generic competition. Investors may want to take a closer look at biotech firms successfully getting drugs through trials for the best long-term growth prospects. Read for technical analysis on Arena Pharmaceuticals Inc. and ARIAD Pharmaceuticals Inc. at
About Street Bulls
STREET BULLS is committed to provide the investor community with sharp and timely trading and investing advice. Our aim is to help our readers achieve above-average returns from the markets and create wealth for themselves. Our newsletters and trading advice will provide investors with the information they need for success in today's volatile markets.
To view our disclaimer, use this link